Boyiadzis, M., Bishop, M. R., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., Van Besien, K., Bergsagel, P. L., Borrello, I., Brody, J., Brufsky, J., Cairo, M., Chari, A., Cohen, A., Cortes, J., Forman, S. J., Friedberg, J. W., Fuchs, E. J., Gore, S. D., Jagannath, S., Kahl, B. S., Kline, J., Kochenderfer, J. N., Kwak, L. W., Levy, R., de Lima, M., Litzow, M. R., Mahindra, A., Miller, J., Munshi, N. C., Orlowski, R. Z., Pagel, J. M., Porter, D. L., Russell, S. J., Schwartz, K., Shipp, M. A., Siegel, D., Stone, R. M., Tallman, M. S., Timmerman, J. M., Van Rhee, F., Waller, E. K., Welsh, A., Werner, M., Wiernik, P. H., & Dhodapkar, M. V. (2016). the Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. Journal for immunotherapy of cancer, 4(1), . http://access.bl.uk/ark:/81055/vdc_100144509749.0x000010